Log in

Kura Oncology Stock Forecast, Price & News

+1.18 (+4.10 %)
(As of 09/28/2020 02:07 AM ET)
Today's Range
Now: $29.98
50-Day Range
MA: $24.00
52-Week Range
Now: $29.98
Volume725,900 shs
Average Volume562,155 shs
Market Capitalization$1.69 billion
P/E RatioN/A
Dividend YieldN/A
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. The company was founded in 2014 and is headquartered in San Diego, California.
Read More
Kura Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.02 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KURA



Sales & Book Value

Annual SalesN/A
Book Value$4.83 per share


Net Income$-63,140,000.00


Market Cap$1.69 billion
Next Earnings Date11/3/2020 (Estimated)
+1.18 (+4.10 %)
(As of 09/28/2020 02:07 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

How has Kura Oncology's stock been impacted by COVID-19?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KURA stock has increased by 210.7% and is now trading at $29.98.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Kura Oncology?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kura Oncology

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Kura Oncology

How were Kura Oncology's earnings last quarter?

Kura Oncology Inc (NASDAQ:KURA) released its earnings results on Thursday, August, 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.42) by $0.02.
View Kura Oncology's earnings history

What price target have analysts set for KURA?

8 analysts have issued twelve-month target prices for Kura Oncology's shares. Their forecasts range from $22.00 to $32.00. On average, they anticipate Kura Oncology's stock price to reach $27.14 in the next twelve months. This suggests that the stock has a possible downside of 9.5%.
View analysts' price targets for Kura Oncology

Who are some of Kura Oncology's key competitors?

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA) and AbbVie (ABBV).

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:
  • Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 50)
  • Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 54)
  • Dr. Marc Grasso, CFO & Chief Bus. Officer
  • Mr. John Farnam, Chief Operating Officer
  • Mr. Pete De Spain, VP of Investor Relations & Corp. Communications

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (14.37%), BVF Inc. IL (4.93%), Vanguard Group Inc. (4.74%), Victory Capital Management Inc. (4.47%), Holocene Advisors LP (1.59%) and Nuveen Asset Management LLC (1.40%). Company insiders that own Kura Oncology stock include Antonio Gualberto, Ecor1 Capital Fund Qualified,, Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology

Which institutional investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP, Victory Capital Management Inc., Arch Venture Corp, WCM Investment Management LLC, Alethea Capital Management LLC, Cormorant Asset Management LP, Capital Impact Advisors LLC, and PDT Partners LLC. Company insiders that have sold Kura Oncology company stock in the last year include Kathleen Ford, Marc Grasso, and Troy Edward Wilson.
View insider buying and selling activity for Kura Oncology

Which institutional investors are buying Kura Oncology stock?

KURA stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Holocene Advisors LP, Sofinnova Investments Inc., Goldman Sachs Group Inc., Vanguard Group Inc., Nuveen Asset Management LLC, BVF Inc. IL, and Candriam Luxembourg S.C.A..
View insider buying and selling activity for Kura Oncology

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $29.98.

How big of a company is Kura Oncology?

Kura Oncology has a market capitalization of $1.69 billion. The company earns $-63,140,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Kura Oncology employs 43 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is www.kuraoncology.com.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at 858-500-8800 or via email at [email protected]

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.